TORONTO--(BUSINESS WIRE)--CellAegis Devices, Inc., announced today the first clinical program to evaluate the use of the Company’s autoRIC™ Device for remote ischemic conditioning (RIC) in patients with evolving ST-elevation myocardial infarction (STEMI). CellAegis’ autoRIC Device provides a noninvasive, safe and accurate device to automate RIC at the point of care. CellAegis’ autoRIC Device is CE Marked and has been developed for acute care applications in the ambulance, emergency room and other hospital settings, as well as for chronic treatment in the home.
